FT-ICR mass spectrometry of metalloproteins

Fourier transform ion cyclotron mass spectrometry (FT-ICR MS) has been used to study a number of metalloproteins. The combination of high-resolution and mass-accuracy, along with fragmentation techniques such as CID, IRMPD and ECD, is shown to be a powerful method to probe metalloproteins and metall...

Full description

Bibliographic Details
Main Author: Weidt, Stefan K.
Published: University of Edinburgh 2008
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.663616
id ndltd-bl.uk-oai-ethos.bl.uk-663616
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-6636162016-02-03T03:17:53ZFT-ICR mass spectrometry of metalloproteinsWeidt, Stefan K.2008Fourier transform ion cyclotron mass spectrometry (FT-ICR MS) has been used to study a number of metalloproteins. The combination of high-resolution and mass-accuracy, along with fragmentation techniques such as CID, IRMPD and ECD, is shown to be a powerful method to probe metalloproteins and metallodrug interactions. The inherent high resolving power and mass measurement accuracy of the FT-ICR MS also enables the oxidation state of the metal present in a metalloprotein to be identified from the isotopically resolved spectra. Carbonic anhydrase II (29 kDa) is an enzyme that catalyses the reversible hydration of carbon dioxide and contains one Zn<sup>2+</sup> ion. To investigate non-covalent protein-drug interactions, the inhibitor acetazolamide was added to a sample of carbonic anhydrase II. Nozzle-skimmer CID, IRMPD and titration methods were used to probe the strength of interaction of the carbonic anhydrase-acetazolamide complex. It was found that lower charge-states bind more strongly than higher charge-states suggesting that the protein unfolds when more protons are bound. FT-ICR MS was used to investigate the nature of adducts between the platinum anti-cancer drug cisplatin, and SOD. The structure showed a cisplatin adduct at His19 of beSOD, which had retained the chloride ligands; these are usually lost in aqueous conditions. After incubation with cisplatin, the mono-platinated species was the most prominent adduct observed. The use of <sup>15</sup>N-labelled cisplatin led to unambiguous assignment of the two ammonia ligands being retained after binding to beSOD, supporting established cisplatin solution behaviour. Mass spectra of heSOD were more complex than those for beSOD due to phosphate buffer adducts and the loss or substitution of the chloride ligands. ECD fragmentation spectra of the isolated mono-platinum adduct of beSOD were used in order to localise the site of modification.571.4University of Edinburghhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.663616http://hdl.handle.net/1842/12146Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 571.4
spellingShingle 571.4
Weidt, Stefan K.
FT-ICR mass spectrometry of metalloproteins
description Fourier transform ion cyclotron mass spectrometry (FT-ICR MS) has been used to study a number of metalloproteins. The combination of high-resolution and mass-accuracy, along with fragmentation techniques such as CID, IRMPD and ECD, is shown to be a powerful method to probe metalloproteins and metallodrug interactions. The inherent high resolving power and mass measurement accuracy of the FT-ICR MS also enables the oxidation state of the metal present in a metalloprotein to be identified from the isotopically resolved spectra. Carbonic anhydrase II (29 kDa) is an enzyme that catalyses the reversible hydration of carbon dioxide and contains one Zn<sup>2+</sup> ion. To investigate non-covalent protein-drug interactions, the inhibitor acetazolamide was added to a sample of carbonic anhydrase II. Nozzle-skimmer CID, IRMPD and titration methods were used to probe the strength of interaction of the carbonic anhydrase-acetazolamide complex. It was found that lower charge-states bind more strongly than higher charge-states suggesting that the protein unfolds when more protons are bound. FT-ICR MS was used to investigate the nature of adducts between the platinum anti-cancer drug cisplatin, and SOD. The structure showed a cisplatin adduct at His19 of beSOD, which had retained the chloride ligands; these are usually lost in aqueous conditions. After incubation with cisplatin, the mono-platinated species was the most prominent adduct observed. The use of <sup>15</sup>N-labelled cisplatin led to unambiguous assignment of the two ammonia ligands being retained after binding to beSOD, supporting established cisplatin solution behaviour. Mass spectra of heSOD were more complex than those for beSOD due to phosphate buffer adducts and the loss or substitution of the chloride ligands. ECD fragmentation spectra of the isolated mono-platinum adduct of beSOD were used in order to localise the site of modification.
author Weidt, Stefan K.
author_facet Weidt, Stefan K.
author_sort Weidt, Stefan K.
title FT-ICR mass spectrometry of metalloproteins
title_short FT-ICR mass spectrometry of metalloproteins
title_full FT-ICR mass spectrometry of metalloproteins
title_fullStr FT-ICR mass spectrometry of metalloproteins
title_full_unstemmed FT-ICR mass spectrometry of metalloproteins
title_sort ft-icr mass spectrometry of metalloproteins
publisher University of Edinburgh
publishDate 2008
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.663616
work_keys_str_mv AT weidtstefank fticrmassspectrometryofmetalloproteins
_version_ 1718176427812061184